

supplementary Table 9. Summary of drug repositioning for ALC and supporting evidence

Predicted drugs	P-value	Hepatotoxicity	Experimental evidence for ALC	Experimental evidence for other liver diseases	Clinical evidence for ALC	Clinical evidence for other liver diseases
Tocilizumab	4.70E-06	Exist				
Lenalidomide	0.001246397	None	24739012	23648434		
Everolimus	0.001303822	Exist	33715287	25081431		
Losartan	0.00419638	None	19416517	28419124		
Lamivudine	0.005682866	Exist				
Vincristine	0.008574555	Exist				
Paricalcitol	0.010234558	None	33872698			
Decitabine	0.010437831	None				25895027
Ascorbic acid	0.015096257	None	24239723		15820479	
Bortezomib	0.015962682	None		24380732		
Azacitidine	0.017408745	None				
Thalidomide	0.017420423	None	12105857		14687169	
Sorafenib	0.018126121	Exist				
Docetaxel	0.020628712	None				
Imiquimod	0.021640594	None				

The numbers shown in the table represent PubMed Identifier (PMID) numbers, which provide evidence for the foundational research and clinical studies supporting the therapeutic effects of the respective drugs.
ALC, alcohol-related cirrhosis.